- Pharmaceutical Products
- Products By Brand Name
- Products By Dosage Form
- Products By Generic Name
- Products By Therapeutic Class
Find a product
Find Generic
Sitadus M
Sitagliptin + Metformin HCL USP
Description:
Sitadus M® ER is a fixed dose combination of two antihyperglycemic agents with different mechanisms of action. Sitagliptin is a member of the DPP-4 (dipeptidyl-peptidase-4) inhibitor class and Metformin hydrochloride is a member of the biguanide.
Sitadus M® ER is a fixed dose combination of two antihyperglycemic agents with different mechanisms of action. Sitagliptin is a member of the DPP-4 (dipeptidyl-peptidase-4) inhibitor class and Metformin hydrochloride is a member of the biguanide.
Indications:
Sitadus M® ER is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus when treatment with both Sitagliptin and Metformin extended release is appropriate
Sitadus M® ER is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus when treatment with both Sitagliptin and Metformin extended release is appropriate
Mode of Action:
Sitagliptin inhibits dipeptidyl peptidase 4 (DPP-4), the enzyme responsible for the inactivation of the incretin hormones which are released into the circulation in response to food intake. Inhibition of DPP-4, results in higher levels of active incretin hormones, stimulating insulin release and reducing glucagon release in a glucose dependent manner.
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Sitagliptin inhibits dipeptidyl peptidase 4 (DPP-4), the enzyme responsible for the inactivation of the incretin hormones which are released into the circulation in response to food intake. Inhibition of DPP-4, results in higher levels of active incretin hormones, stimulating insulin release and reducing glucagon release in a glucose dependent manner.
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Other Brands From Same Therapeutic Class
